Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Efavirenz · 2 trials · 2 indications
QTcF = QT corrected for Fridericia's formula
| Arm | Type | Description |
|---|---|---|
| Moxifloxacin, Placebo, Efavirenz | EXPERIMENTAL | Moxifloxacin, Placebo, Efavirenz single dose as specified |
| Name | Type | Description |
|---|---|---|
| Efavirenz | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Moxifloxacin | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria Patients may be eligible for this study if they: * Are at least 18 years old. Patients living in USA, Puerto Rico, Australia, Brazil, Singapore, and Thailand can be at least 12 years old (need consent of parent or guardian if under 18). * Have a viral load of at least 2,000 copi...
Top 20 of 28 competitors
Efavirenz is used for HIV infections and HIV/AIDS. It is a small molecule being developed by Bristol-Myers Squibb Company for the treatment of these infectious disease conditions. The drug has been studied in clinical trials involving patients with HIV infections.
Efavirenz is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company has conducted clinical trials to evaluate the drug's effectiveness and safety in treating HIV infections and HIV/AIDS.
Efavirenz is in Phase 3 clinical development. It has completed one Phase 3 trial with 730 participants and one Phase 1 trial with 58 healthy volunteers. The drug remains investigational and is not yet approved for commercial use.
Efavirenz has been studied in two completed trials. NCT00005918 was a Phase 3 study of stavudine forms in HIV-infected patients with 730 participants. NCT02164812 was a Phase 1 study of Efavirenz's effect on ECG QTcF interval in healthy subjects with 58 participants.
Efavirenz is a small molecule developed for HIV infections. As a non-nucleoside reverse transcriptase inhibitor, it works by blocking the reverse transcriptase enzyme that HIV needs to replicate. This mechanism helps reduce viral load in patients with HIV/AIDS.